Anti-platelet therapy does not significantly reduce pain crises in sickle cell disease

Treatment with the antiplatelet agent prasugrel does not significantly reduce the rate of pain crises or severe lung complications in children with sickle cell disease, according to a report describing one of the largest and most geographically diverse international clinical trials on sickle cell disease to date.

Read the whole article on Science Daily

More from Science Daily